Related Experiment Video
Updated: Aug 8, 2026
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
Effect of preS2 antisense RNA on hepatocellular carcinoma with a novel delivery system
Chunhong Ma1, Wensheng Sun, Peikun Tian
1Institute of Immunology, Medical College, Shandong University, Ji'nan 250012, China.
Objectives:
To construct a hepatoma directed gene delivery system which could transfer preS2 antisense RNA to liver cancer cells specifically, and to explore a new therapeutic strategy for hepatocellular carcinoma by blocking hepatitis B virus (HBV) with antisense RNA targeting hepatocellular carcinoma.
Methods:
GE7 and HA20 were synthesized and mixed with pEBAF-as-preS2, a hepatocarcinoma specific HBV antisense expression vector, to construct a novel HBV antisense RNA delivery system named AFP-enhancing 4-element complex. Nude mice bearing hepatocelluar carcinoma cells HepG2.2.15 were injected with AFP-enhancing 4-element complex via a tail vein. Total RNA from tissues was extracted, and reversal transcription-ploymerase chain reaction (RT-PCR) was used to detect the expression of preS2. Different doses of AFP-enhancing 4-element complex was injected into nude mice at different time points, and tumor diameter was measured.
Results:
AFP-enhancing 4-element complex was constructed successfully. RT-PCR showed preS2 antisense RNA delivered by AFP-enhancing 4-element complex only expressed in liver tumor HepG2.2.15 cells of the mice. After the treatment of AFP-enhancing 4-element complex with dose of 0.2 micro g per mouse (once a week for 4 weeks), the mean tumor diameter of nude mice was significantly shorter than that of the control groups (0.995 +/- 0.35 cm vs 2.125 +/- 0.25 cm, P < 0.01).
Conclusions:
An HBV antisense RNA gene delivery system targeting hepatocellular carcinoma, AFP-enhancing 4-element complex, was constructed successfully. PreS2 antisense RNA expressed specifically in hepatocelluar carcinoma cells significantly inhibits tumor growth of mice bearing hepatocarcinoma HepG2.2.15 and may have therapeutic potential in HBV related hepatocarcinoma.
Insights
A novel gene delivery system, AFP-enhancing 4-element complex, successfully targeted liver cancer cells with preS2 antisense RNA. This therapeutic strategy significantly inhibited hepatocellular carcinoma tumor growth in mice.
Area of Science:
- Hepatocellular Carcinoma Research
- Gene Therapy
- Hepatitis B Virus (HBV) Therapeutics
Background:
- Hepatocellular carcinoma (HCC) is a major global health concern, often linked to Hepatitis B Virus (HBV) infection.
- Developing targeted gene delivery systems is crucial for effective HCC treatment.
- Antisense RNA offers a potential strategy to inhibit viral replication and tumor growth.
Purpose of the Study:
- To construct a targeted gene delivery system for preS2 antisense RNA in liver cancer.
- To evaluate the therapeutic potential of this system against HBV-related hepatocellular carcinoma.
- To explore a novel strategy for blocking HBV in HCC.
Main Methods:
- Synthesis of GE7 and HA20 components to form the AFP-enhancing 4-element complex.
- Development of a hepatocarcinoma-specific HBV antisense expression vector (pEBAF-as-preS2).
- In vivo testing in nude mice bearing HepG2.2.15 HCC cells, followed by RT-PCR analysis and tumor measurement.
Main Results:
- Successful construction and validation of the AFP-enhancing 4-element complex.
- Specific expression of preS2 antisense RNA in HepG2.2.15 liver tumor cells.
- Significant reduction in tumor diameter (0.995 cm vs 2.125 cm) in treated mice compared to controls (P < 0.01).
Conclusions:
- The AFP-enhancing 4-element complex is an effective gene delivery system for hepatocellular carcinoma.
- Targeted delivery of preS2 antisense RNA specifically inhibits HCC tumor growth.
- This approach shows therapeutic promise for HBV-related hepatocarcinoma.
More Related Videos
Related Concept Videos
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi